September 18, 2006August 12, 2018
Dear Fellow InNexus Shareholders,
I must first begin by thanking you for your wishes and support on my recent appointment to President, CEO & Chairman. The entire team at InNexus has been diligently contributing toward our growth and the recent management change reinforces how best we can apply our talents and ready us for success with our technology, projects and partners.
Before I speak on what we have planned for the coming year, let me discuss our industry. Monoclonal antibodies are emerging as critical tools in biochemistry, molecular biology and medicine. Their novelty and wide application for cancer, cardiovascular and other hard-to-treat diseases make them the drug development platform of choice for the pharmaceutical industry. Record numbers of antibodies are either in early or advanced states of development and numerous pharma analysts agree that antibodies minimize side effects and are more likely to be cost-effective in the long run, reducing disease recurrence and hospitalization. The stellar results of recent product launches have only added to antibodies attractiveness and InNexus is positioned to win.
2007 is looking to be an exciting year. We will focus on creating value from our proprietary antibody enhancement technology, form new partnerships with pharma and biotech companies, and stimulate the growth of our company by building a development-stage product portfolio. Thank you again for your support as we continue our commitment of developing commercial opportunities and great medicines.
Lastly, please join me in thanking our talented and committed team of employees and their successful efforts during 2006.
President, CEO & Chairman